1. Optimization of nanostructured lipid carriers for Zidovudine delivery using a microwave-assisted production method
- Author
-
José Lamartine Soares-Sobrinho, S.M.T. Cavalcanti, S.A. Costa Lima, Cláudia Nunes, and Salette Reis
- Subjects
Materials science ,Anti-HIV Agents ,Cell Survival ,Drug Compounding ,Sonication ,Dispersity ,Pharmaceutical Science ,Nanoparticle ,02 engineering and technology ,030226 pharmacology & pharmacy ,Microwave assisted ,Quality by Design ,Diglycerides ,Jurkat Cells ,03 medical and health sciences ,Zidovudine ,0302 clinical medicine ,Drug Stability ,medicine ,Humans ,Microwaves ,Triglycerides ,Drug Carriers ,021001 nanoscience & nanotechnology ,Controlled release ,Nanostructures ,Drug Liberation ,Chemical engineering ,Emulsions ,Particle size ,0210 nano-technology ,medicine.drug - Abstract
An adapted methodology for obtaining lipid nanoparticles that only uses the microwave reactor in the synthesis process was developed. The method has the following features: one-pot, one-step, fast, practical, economical, safe, readiness of scaling-up, lack of organic solvents and production of nanoparticles with low polydispersity index (PDI) (below 0.3). This new method was applied for the development of nanostructured lipid carriers (NLC) loaded with a hydrophilic drug, the antiretroviral agent zidovudine (AZT). The aim of the present work was to develop, evaluate and compare optimized NLC formulations produced by two different methods - hot ultrasonication and microwave-assisted method. The development and optimization of the NLC formulations were supported by a Quality by Design (QbD) approach. All formulations were physicochemically characterized by the same parameters. The optimized formulations presented a suitable profile for oral administration (particle size between 100 and 300 nm, PDI 0.3 and negative zeta potential-20 mV). Furthermore, the morphologies assessed by TEM showed spherical shape and confirmed the results obtained by DLS. Both AZT loaded formulations were physically stable for at least 45 days and non-toxic on Jurkat T cells. Drug release studies showed a controlled release of AZT under gastric and plasma-simulated conditions.
- Published
- 2018
- Full Text
- View/download PDF